Growing bipartisan frustration with pharmacy benefit managers has led to regulatory action in several states, with Tennessee and Arkansas taking steps to rein in their influence. Both lawmakers and patients—regardless of political affiliation—have expressed concerns over the role these middlemen play in prescription drug costs. The push for oversight reflects deep dissatisfaction with how these companies negotiate drug prices and affect patient access to medications. As more states consider similar measures, the debate over their accountability continues to gain momentum.
Republicans and Democrats, both patients and politicians, seem united in their disdain for the healthcare companies known as pharmacy benefit managers. Tennessee and Arkansas are regulating them now.
